Sue Hughes

With growing evidence that loneliness increases the risk for multiple diseases, there are questions about the mechanisms at play and what clinicians can do to help patients.

CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and obesity

Aspirin may be of specific benefit for the primary prevention of cardiovascular disease in individuals with raised Lp(a) levels, a new study has suggested.

CHICAGO — An intensive treatment approach to lower systolic blood pressure to a target of 120 mm Hg in patients with type 2 diabetes led to a lower

The routine administration of spironolactone to patients after a myocardial infarction (MI) did not reduce either of the coprimary outcomes in the CLEAR SYNERGY (OASIS 9) trial.

Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ENBALV trial, but the event rate was too low to draw definitive conclusions.

The risk of arterial and venous thrombosis in patients with COVID-19 has been a major issue throughout the pandemic, and how best to manage this risk is the subject of a new review article.

A new lipid-lowering agent in a class that had been written off by many is being developed by a group of academic experts, with new data showing large LDL reductions on top of high-intensity statins.

Do We Need Cardiovascular Risk Equations to Guide Statin Use?

An individual's estimated risk of having a heart attack or stroke in the next 10 years is widely used to guide preventative medication prescriptions